Abstract: Fumaric acid derivatives and ophthalmic lenses using them are disclosed. More specifically, a fumaric acid derivative having a hydrophilic group and a silicon-containing alkyl group within a molecule, and contact lenses or intraocular lenses using the same are disclosed. The fumaric acid derivatives of the present invention provide, on one hand, superior oxygen permeability by having a silicon-containing alkyl group within the molecular structure, and on the other hand, improved compatibility with other hydrophilic monomers by having a hydrophilic group within the same molecule. When ophthalmic lenses obtained by polymerizing monomer compositions containing the fumaric acid derivative are constructed as, for example, water content lenses, lenses with high oxygen permeability independent from the water content may be obtained, wherein the fumaric acid derivatives is superior in compatibility with the hydrophilic monomer used in combination and allows the combination in various mixing ratios.

Abstract: An ion-selective electrode has a responsive glass membrane with an exterior thin film containing titanium dioxide of an anatase type that is continuously formed as an integrated body. The thin film, of several hundred nm in numbers, is electrically connected by an amount of titanium dioxide that will form a continuity in the thin film structure. The thin film can be porous and contain at least one metal selected from cobalt, nickel, tungsten, copper, platinum, gold, silver and iron. Additionally, significantly larger titanium dioxide particles of 0.02 ?m in diameter can be further mixed into the thin film.

Abstract: A group 3-5 nitride semiconductor multilayer substrate (1) and a method for manufacturing such substrate are provided. A semiconductor layer (12) is formed on a base substrate (11), and a mask (13) is formed on the semiconductor layer (12). Then, after forming a group 3-5 nitride semiconductor crystalline layer (14) by selective growing, the group 3-5 nitride semiconductor crystalline layer (14) and the base substrate (11) are separated. The crystallinity of the semiconductor layer (12) is lower than that of the group 3-5 nitride semiconductor crystalline layer (14).

Abstract: The present invention relates to uses of PCI, which inhibits HGFa activity, and to uses of anti-PCI antibodies, which neutralize HGFa inhibition; and to agents for regulating and controlling tissue regeneration and/or repair, with PCI as an active ingredient; and to agents for enhancing tissue regeneration and/or repair, with anti-PCI antibodies as active ingredients (particularly, anti-PCI antibodies with the action of neutralizing PCI (anti-PCI neutralizing antibodies)).

Abstract: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4143-151-specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

Abstract: Disclosed is a sensitive glass film for a pH electrode, which is not deteriorated in its glass strength or pH-measuring function, which is hardly stained, and from which any stain can be removed easily. Also disclosed is a pH electrode having the sensitive glass film. A microparticle comprising rutile-type or brookite-type titanium dioxide or a microparticle comprising amorphous titanium dioxide is adhered directly on the glass film surface of a sensitive glass film for a pH electrode.

Abstract: Disclosed is a sensitive glass film for a pH electrode, which is not deteriorated in its glass strength or pH-measuring function, which is hardly stained, and from which any stain can be removed easily. Also disclosed is a pH electrode having the sensitive glass film. A microparticle comprising rutile-type or brookite-type titanium dioxide or a microparticle comprising amorphous titanium dioxide is adhered directly on the glass film surface of a sensitive glass film for a pH electrode.

Abstract: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4143-151-specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

Abstract: The present claimed invention intends to provide a responsive glass membrane for ion selective electrode glass and an ion selective electrode comprising the responsive glass membrane that produces a self-cleaning function when the ultraviolet rays are irradiated although no change is brought in a composition of a sample solution as being an object to be measured and that is low in electric resistance value and superior in responsivity under an ordinary measurement environment. The responsive glass membrane for ion selective electrode is made of the titanium-containing oxide glass that contains 20˜80 mol % of titanium dioxide and lithium oxide.

Abstract: A group 3-5 nitride semiconductor multilayer substrate (1) and a method for manufacturing such substrate are provided. A semiconductor layer (12) is formed on a base substrate (11), and a mask (13) is formed on the semiconductor layer (12). Then, after forming a group 3-5 nitride semiconductor crystalline layer (14) by selective growing, the group 3-5 nitride semiconductor crystalline layer (14) and the base substrate (11) are separated. The crystallinity of the semiconductor layer (12) is lower than that of the group 3-5 nitride semiconductor crystalline layer (14).

Abstract: [Problems] The objective is to provide a new low-toxic drug for external use for intractable diseases, such as erosion, decubitus, and skin ulcer, that prevents cicatrization and reduces iodine accumulation on wound surfaces with sufficiently promoting healing. [Means for solving problem] Preparation of a wound treatment drug for external use containing oily bases and iodine but substantially no white soft sugar, which is a characteristic of the drug of this invention. The invented drug prevents infection through the wound surface due to a sufficient bactericidal effect of iodine, and promotes wound healing, prevents cicatrization and reduces iodine accumulation on the wound surface by maintenance of appropriate moisture in the wound surface due to a moisturizing effect of oily bases.

Abstract: The present invention provides Ti-4 protein, which is a protein obtained from salivary gland of Triatoma infestans, and the present invention provides Ti-4 gene encoding the protein. As the Ti-4 protein exhibits inhibitory activity on platelet aggregation, a medicine comprising the Ti-4 protein as an active ingredient will serve as a platelet aggregation inhibitor possibly effective for prevention and treatment of myocardial infarction, pulmonary infarction and cerebral infarction. Moreover, the Ti-4 protein will also serve as a highly prospective lead compound in the development of novel platelet aggregation inhibitors.

Abstract: The invention relates to TAFI inhibitors and their use to treat pulmonary fibrosis.

Abstract: The present invention provides Ti-3 protein, which is a protein obtained from salivary gland of Triatoma infestans, and the present invention provides Ti-3 gene encoding the protein. As the Ti-3 protein exhibits inhibitory activity on platelet aggregation, a medicine comprising the Ti-3 protein as an active ingredient will serve as a platelet aggregation inhibitor possibly effective for prevention and treatment of myocardial infarction, pulmonary infarction and cerebral infarction. Moreover, the Ti-3 protein will also serve as a highly prospective lead compound in the development of novel platelet aggregation inhibitors.

Abstract: The present invention provides Ti-4 protein, which is a protein obtained from salivary gland of Triatoma infestans, and the present invention provides Ti-4 gene encoding the protein. As the Ti-4 protein exhibits inhibitory activity on platelet aggregation, a medicine comprising the Ti-4 protein as an active ingredient will serve as a platelet aggregation inhibitor possibly effective for prevention and treatment of myocardial infarction, pulmonary infarction and cerebral infarction. Moreover, the Ti-4 protein will also serve as a highly prospective lead compound in the development of novel platelet aggregation inhibitors.

Abstract: The present invention provides Ti-3 protein, which is a protein obtained from salivary gland of Triatoma infestans, and the present invention provides Ti-3 gene encoding the protein. As the Ti-3 protein exhibits inhibitory activity on platelet aggregation, a medicine comprising the Ti-3 protein as an active ingredient will serve as a platelet aggregation inhibitor possibly effective for prevention and treatment of myocardial infarction, pulmonary infarction and cerebral infarction. Moreover, the Ti-3 protein will also serve as a highly prospective lead compound in the development of novel platelet aggregation inhibitors.